Compare Stocks: CCEL, XGN, BNR, and SERA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNR Burning Rock Biotech	$8.97 +1.5%	$9.16	$6.00 ▼ $41.72	$92.98M	1.34	15,605 shs	2,910 shs
CCEL Cryo-Cell International	$3.56 +2.3%	$3.51	$2.72 ▼ $5.43	$28.06M	0.48	8,822 shs	10,868 shs
SERA Sera Prognostics	$1.93 -8.1%	$2.01	$1.56 ▼ $3.95	$82.23M	0.96	34,890 shs	87,165 shs
XGN Exagen	$6.45 +37.8%	$4.61	$2.59 ▼ $12.23	$113.07M	2.05	234,136 shs	2.62 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNR Burning Rock Biotech	+1.47%	-0.12%	-8.66%	-47.27%	+45.85%
CCEL Cryo-Cell International	+2.30%	+5.33%	+6.59%	+0.85%	-30.33%
SERA Sera Prognostics	-8.10%	-4.93%	-3.50%	+6.63%	-25.48%
XGN Exagen	+37.82%	+44.94%	+42.07%	+108.74%	-27.12%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNR Burning Rock Biotech	$8.97 +1.5%	$9.16	$6.00 ▼ $41.72	$92.98M	1.34	15,605 shs	2,910 shs
CCEL Cryo-Cell International	$3.56 +2.3%	$3.51	$2.72 ▼ $5.43	$28.06M	0.48	8,822 shs	10,868 shs
SERA Sera Prognostics	$1.93 -8.1%	$2.01	$1.56 ▼ $3.95	$82.23M	0.96	34,890 shs	87,165 shs
XGN Exagen	$6.45 +37.8%	$4.61	$2.59 ▼ $12.23	$113.07M	2.05	234,136 shs	2.62 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNR Burning Rock Biotech	+1.47%	-0.12%	-8.66%	-47.27%	+45.85%
CCEL Cryo-Cell International	+2.30%	+5.33%	+6.59%	+0.85%	-30.33%
SERA Sera Prognostics	-8.10%	-4.93%	-3.50%	+6.63%	-25.48%
XGN Exagen	+37.82%	+44.94%	+42.07%	+108.74%	-27.12%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNR Burning Rock Biotech	1.00	Sell	N/A	N/A
CCEL Cryo-Cell International	2.00	Hold	N/A	N/A
SERA Sera Prognostics	2.67	Moderate Buy	$5.50	184.97% Upside
XGN Exagen	2.89	Moderate Buy	$9.00	39.53% Upside

Current Analyst Ratings Breakdown

Latest CCEL, XGN, BNR, and SERA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/31/2026	SERA Sera Prognostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/16/2026	SERA Sera Prognostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/24/2026	XGN Exagen	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$8.00
6/24/2026	XGN Exagen	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
6/17/2026	SERA Sera Prognostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/4/2026	SERA Sera Prognostics	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.00
5/12/2026	XGN Exagen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/12/2026	XGN Exagen	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$9.00 ➝ $8.00

(Data available from 8/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNR Burning Rock Biotech	$77.16M	1.22	N/A	N/A	$7.28 per share	1.23
CCEL Cryo-Cell International	$31.57M	0.91	N/A	N/A	($2.31) per share	-1.54
SERA Sera Prognostics	$80K	944.74	N/A	N/A	$1.94 per share	0.99
XGN Exagen	$66.57M	2.34	N/A	N/A	$0.77 per share	8.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNR Burning Rock Biotech	-$7.92M	-$0.82	N/A	N/A	N/A	-11.57%	-10.98%	-7.33%	9/2/2026 (Estimated)
CCEL Cryo-Cell International	-$2.43M	-$1.06	N/A	N/A	N/A	-7.92%	N/A	-4.00%	N/A
SERA Sera Prognostics	-$31.93M	-$0.65	N/A	N/A	N/A	-56,385.97%	-41.02%	-30.95%	8/12/2026 (Estimated)
XGN Exagen	-$19.95M	-$0.89	N/A	N/A	N/A	-29.49%	-94.37%	-28.96%	N/A

Latest CCEL, XGN, BNR, and SERA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2026	Q2 2026	BNR Burning Rock Biotech	-$2.2883	N/A	N/A	N/A	$19.21 million	N/A
8/12/2026	Q2 2026	SERA Sera Prognostics	-$0.14	N/A	N/A	N/A	$0.07 million	N/A
8/4/2026	Q2 2026	XGN Exagen	-$0.1914	-$0.13	+$0.0614	-$0.13	$17.80 million	$19.94 million
7/15/2026	Q2 2026	CCEL Cryo-Cell International	N/A	$0.07	N/A	$0.07	N/A	$7.78 million
6/9/2026	Q1 2026	BNR Burning Rock Biotech	-$2.2884	-$0.20	+$2.0884	-$0.25	$19.21 million	$15.66 million
5/11/2026	Q1 2026	XGN Exagen	-$0.24	-$0.17	+$0.07	-$0.17	$16.41 million	$17.31 million
5/6/2026	Q1 2026	SERA Sera Prognostics	-$0.16	-$0.17	-$0.01	-$0.17	$0.07 million	$0.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNR Burning Rock Biotech	N/A	N/A	N/A	N/A	N/A
CCEL Cryo-Cell International	N/A	N/A	N/A	N/A	N/A
SERA Sera Prognostics	N/A	N/A	N/A	N/A	N/A
XGN Exagen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNR Burning Rock Biotech	0.06	3.05	2.81
CCEL Cryo-Cell International	N/A	0.71	0.69
SERA Sera Prognostics	N/A	2.12	2.12
XGN Exagen	1.67	3.47	3.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNR Burning Rock Biotech	30.03%
CCEL Cryo-Cell International	10.44%
SERA Sera Prognostics	54.64%
XGN Exagen	75.25%

Insider Ownership

Company	Insider Ownership
BNR Burning Rock Biotech	30.30%
CCEL Cryo-Cell International	38.59%
SERA Sera Prognostics	11.30%
XGN Exagen	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNR Burning Rock Biotech	1,390	10.52 million	7.33 million	Not Optionable
CCEL Cryo-Cell International	90	8.06 million	4.95 million	Not Optionable
SERA Sera Prognostics	120	39.16 million	34.73 million	Optionable
XGN Exagen	220	24.16 million	21.65 million	Optionable

CCEL, XGN, BNR, and SERA Headlines

Recent News About These Companies

Exagen Inc (XGN) (Q2 2026) Earnings Call Highlights: Record Revenue and Path to Profitability

August 4 at 7:46 PM | finance.yahoo.com

Exagen Q2 Earnings Call Highlights

August 4 at 3:03 PM | marketbeat.com

Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript

August 4 at 3:00 PM | seekingalpha.com

Exagen Inc. Reports Second Quarter 2026 Financial Results

August 4 at 2:45 PM | markets.businessinsider.com

Exagen reports record second-quarter 2026 revenue and raises full-year guidance

August 4 at 2:45 PM | msn.com

Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates

August 4 at 10:21 AM | zacks.com

Exagen (NASDAQ:XGN) Announces Quarterly Earnings Results

August 4 at 9:40 AM | marketbeat.com

Exagen Reports Record Second-Quarter Revenue and Narrows Losses, Raises Full-Year 2026 Guidance

August 4 at 8:31 AM | quiverquant.comQ

Exagen reports record Q2 revenue of $19.9 million

August 4 at 8:11 AM | quiverquant.comQ

Exagen Inc. (NASDAQ:XGN) Receives Consensus Rating of "Moderate Buy" from Analysts

August 2 at 2:14 AM | americanbankingnews.com

Exagen Inc. (NASDAQ:XGN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 2 at 2:13 AM | marketbeat.com

Exagen (XGN) Projected to Release Earnings on Tuesday

July 28, 2026 | marketbeat.com

Exagen Inc. to Participate in Upcoming Investor Conference

July 28, 2026 | globenewswire.com

Exagen: A Small Diagnostics Company Approaching An Inflection Point

July 23, 2026 | seekingalpha.com

Exagen to Announce Second Quarter Financial Results on August 4, 2026

July 21, 2026 | markets.businessinsider.com

Exagen Shareholders Approve Directors, Auditor and Pay Package

June 9, 2026 | tipranks.com

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

June 1, 2026 | globenewswire.com

How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%

May 28, 2026 | zacks.com

Exagen Earnings Call Highlights Growth Amid Key Risks

May 15, 2026 | theglobeandmail.com

The Exagen Inc. (NASDAQ:XGN) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 15, 2026 | finance.yahoo.com

Exagen Inc. (NASDAQ:XGN) Q1 2026 Earnings Call Transcript

May 13, 2026 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CCEL, XGN, BNR, and SERA Company Descriptions

Burning Rock Biotech NASDAQ:BNR

$8.97 +0.13 (+1.47%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$8.81 -0.16 (-1.78%)

As of 08/4/2026 07:34 PM Eastern

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

Cryo-Cell International NYSEAMERICAN:CCEL

$3.56 +0.08 (+2.30%)

Closing price 08/4/2026 04:10 PM Eastern

Extended Trading

$3.56 0.00 (-0.06%)

As of 04:02 AM Eastern

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.

Sera Prognostics NASDAQ:SERA

$1.93 -0.17 (-8.10%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$1.94 +0.01 (+0.52%)

As of 08/4/2026 07:34 PM Eastern

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Exagen NASDAQ:XGN

$6.45 +1.77 (+37.82%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$6.60 +0.15 (+2.31%)

As of 04:06 AM Eastern

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CCEL, XGN, BNR, and SERA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CCEL, XGN, BNR, and SERA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CCEL, XGN, BNR, and SERA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CCEL, XGN, BNR, and SERA Company Descriptions

Burning Rock Biotech NASDAQ:BNR

Cryo-Cell International NYSEAMERICAN:CCEL

Sera Prognostics NASDAQ:SERA

Exagen NASDAQ:XGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CCEL, XGN, BNR, and SERA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CCEL, XGN, BNR, and SERA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CCEL, XGN, BNR, and SERA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CCEL, XGN, BNR, and SERA Company Descriptions

Burning Rock Biotech NASDAQ:BNR

Cryo-Cell International NYSEAMERICAN:CCEL

Sera Prognostics NASDAQ:SERA

Exagen NASDAQ:XGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools